PlumX Metrics
Embed PlumX Metrics

Osilodrostat: First Approval

Drugs, ISSN: 1179-1950, Vol: 80, Issue: 5, Page: 495-500
2020
  • 42
    Citations
  • 0
    Usage
  • 25
    Captures
  • 0
    Mentions
  • 0
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

Review Description

Osilodrostat (Isturisa) is an orally available small molecule 11β-hydroxylase inhibitor that is being developed by Novartis for the treatment of Cushing’s disease. Based on results from a pivotal phase III trial, osilodrostat was approved in the EU for use in the treatment of endogenous Cushing’s syndrome in adults and is under regulatory review in the USA for the treatment of Cushing’s disease. This article summarises the milestones in the development of osilodrostat leading to this first approval.

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know